Berkeley, CA – According to filings with the U.S. Securities and Exchange Commission, Caribou Biosciences is raising $114,999,613.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Rachel Haurwitz played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Caribou Biosciences

Caribou is a leading clinical-stage biotechnology company, founded by pioneers of CRISPR biology, using CRISPR genome editing to discover and develop immune cell-based therapeutics for cancer. Caribou believes that cell therapies are critical now and for the future of cancer therapy and that genome editing is necessary to develop sophisticated cell therapies to treat a variety of different malignancies. The Company is developing a pipeline of genome-edited off-the-shelf CAR-T cell and natural killer (NK) cell therapies for a range of tumor types. Additionally, Caribou offers licenses to its CRISPR-Cas9 foundational IP in multiple fields including research tools, internal research use, diagnostics, and industrial biotechnology.

To learn more about Caribou Biosciences, visit http://cariboubio.com/

Contact:
Rachel Haurwitz, President and Chief Executive Officer
510-982-6030
https://www.linkedin.com/in/rachelhaurwitz/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved